Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Roxithromycin in nongonococcal urethritis.

A Lassus1, A Seppala

  • 1Department of Dermatology and Venereology, University Central Hospital, Helsinki, Finland.

The Journal of Antimicrobial Chemotherapy
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Routine wastewater-based monitoring of antibiotic resistance in two Finnish hospitals: focus on carbapenem resistance genes and genes associated with bacteria causing hospital-acquired infections.

The Journal of hospital infection·2021
Same author

Response to antipsychotic drugs in treatment-resistant schizophrenia: Conclusions based on systematic review.

Schizophrenia research·2016
Same author

Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.

Allergy·2016
Same author

Limits on Anisotropy in the Nanohertz Stochastic Gravitational Wave Background.

Physical review letters·2015
Same author

Prophylactic immunization of mice with phospholipase A2-loaded gas-filled microbubbles is protective against Th2-mediated honeybee venom allergy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Missing driver in the Sun-Earth connection from energetic electron precipitation impacts mesospheric ozone.

Nature communications·2014
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Roxithromycin, at 150 mg twice daily for ten days, demonstrated a 90% clinical success rate in treating non-gonococcal genital infections. This macrolide antibiotic proved as effective as common tetracyclines for nongonococcal urethritis.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Non-gonococcal genital infections (NGGIs) are prevalent, necessitating effective and well-tolerated treatments.
  • Macrolide antibiotics, such as roxithromycin, offer an alternative to traditional therapies like tetracyclines.

Purpose of the Study:

  • To summarize the efficacy and tolerance of roxithromycin in treating NGGIs based on five clinical studies.
  • To compare the effectiveness of roxithromycin with other standard treatments for NGGIs.

Main Methods:

  • A meta-analysis of five studies (three double-blind comparative, two open) involving 924 outpatients with NGGIs.
  • Patients received roxithromycin (150 mg twice daily for ten days) or comparator drugs (doxycycline, lymecycline, or higher-dose roxithromycin).

Related Experiment Videos

Main Results:

  • Roxithromycin 150 mg twice daily achieved an overall clinical success rate of 90% (637 patients).
  • Clinical success rates for roxithromycin 150 mg twice daily were 92% in nongonococcal urethritis and 81% in cervicovaginitis.
  • Bacteriological eradication rates were high, particularly for Chlamydia trachomatis (97%) and Ureaplasma urealyticum (88%).

Conclusions:

  • A ten-day course of roxithromycin 150 mg twice daily is highly effective for NGGIs.
  • Roxithromycin demonstrates comparable efficacy to commonly used tetracyclines for nongonococcal urethritis.
  • Higher daily doses of roxithromycin (over 300 mg) did not provide additional efficacy benefits.